How to Manage and Treat a Psoriatic Arthritis (PsA)
Patient Population to Improve Outcomes
A continuing medical education activity sponsored by NAMCP and AAMCN
This activity was held live at the 2008 Fall Managed Care Forum.

This activity is valid from January 19, 2009 to December 31, 2009
 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from Centocor, Inc and Wyeth Pharmaceuticals
PLEASE CLICK HERE TO VIEW PRESENTATION

 PLEASE CLICK HERE FOR POST TEST AND EVALUATION

Instructions for CME/CEU:  View the presentation, answer the post test, complete the evaluation form and submit to keads@namcp.org.  A score of 70% must be achieved on the post test to receive continuing education credits. You will have the option on the post test/evaluation page to submit your forms electronically or by faxing them to Katie Eads at 804-747-5316.

Summary
Psoriatic arthritis (PsA) is a disabling condition and patients with PsA may have significant morbidity, disability, and early mortality. Newer agents which target tumor necrosis factor (TNF) alpha have been shown to improve all domains of the psoriatic arthritis and are the treatment of choice. There are more agents targeting different aspects of the pathophysiology of this disease on the horizon.

Objectives

  • Describe the role of inflammation in psoriatic arthritis

  • Evaluate current treatment options for psoriatic arthritis

  • Discuss the impact psoriatic arthritis has on the patient's overall health status
Faculty: Philip Mease, MD, Head, Seattle Rheumatology Associates, Chief, Rheumatology Research, Swedish Medical Center, Clinical Professor, University of Washington.
   

Disclosure:

 Dr. Mease has disclosed the following relationships:
Editorial Review Board and or Speakers Fees; Journal of Rheumatology.
The Arthritis Foundation, Genelab Technologies, GlaxoSmithKline, The Lupus Foundation, Merck, The National Psoriasis Foundation, Ortho McNeil, Pfizer, Proctor & Gamble, sanofi aventis, Searle, and Wyeth.
Advisory Boards
Immunex/Wyeth’s Patient Compliance, Immunex/Wyeth’s Psoriatic Arthritis and Psoriasis, Proctor & Gamble Alliance for Better Bone Health, Pfizer Fibromyalgia
  The NAMCP planning committee has no real or perceived financial relationships to disclose.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. NAMCP designates this activity for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses (AAMCN) has been approved as a provider of continuing education by the Virginia Nurses Association (VNA) VNA is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity will be awarded 1.0 contact hours.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

  

This activity is supported by an educational grant from Centocor, Inc and Wyeth Pharmaceuticals